Genesis BioPharma (OTC:GNBP) Looking for Partners at Roth

Genesis Biopharma (OTC:GNBP) announced last week, in a press release, that Anthony Cataldo, President and Chief Executive Officer, and Marvin Hausman M.D., Chief Science Officer, will present to investors at the 23rd Annual Roth Capital Growth Stock Conference on Wednesday, March 16, 2011 at 2:00 p.m. Pacific. The conference is being held March 13-16 at the Ritz Carlton Hotel in Laguna Niguel, California. As I write, shares of the company were down slightly at $1.10 per share on volume of 100,000 shares. Genesis has a market cap of $80 million and a 52-week range between $0.95 and $1.26 per share.

A webcast of the presentation will be accessible online at www.genesis-biopharma.com. An archived version will be available for 30 days.

Some facts from the company Web site:

Genesis is developing a targeted anti-CD55 monoclonal antibody (mAb) technology to neutralize a key cancer defense mechanism that is over-expressed in >80% of tumors. The anti-CD55 technology could provide a safe alternative to toxic chemotherapy regimens, and be used either as a monotherapy or in combination with other approved therapies. The company initially is addressing metastatic colorectal cancer and lymphoma, and is making progress toward an IND filing with the U.S. Food and Drug Administration (FDA).

Genesis plans to seek partnerships with pharmaceutical and biotechnology companies to support clinical development programs at the earliest appropriate time. Genesis, through its Genesis Advanced Development Program (Genesis ADP), is screening combinations of approved drugs for potential cocktail therapies. Genesis ADP has established collaborations with researchers at Wake Forest, SENS Foundation, and the University of California Los Angeles. The company raised $2 million in 2010 with institutional and high-net worth investors and has a clean capital structure with no debt; 1 million options and 1 million warrants, according to the company fact sheet.

For more information about the company, visit www.genesis-biopharma.com.

Distributed by IntelBuilder Social Media Platform

Roth Capital Conference

Genesis Biopharma (OTC:GNBP), a biotechnology company developing targeted cancer therapies, today announced that Anthony Cataldo, President and Chief Executive Officer, and Marvin Hausman M.D., Chief Science Officer, will present to investors at the 23rd Annual Roth Capital Growth Stock Conference on Wednesday, March 16, 2011 at 2:00 p.m. Pacific. The conference is being held March 13-16 at the Ritz Carlton Hotel in Laguna Niguel, California. The company is a lightly traded stock that last traded on February 24, 2011 at a price of $1.26 per share. Genesis Biopharma has a market cap of $92 million and a 52-week range between $0.95 and $1.26 per share.

A webcast of the presentation will be accessible online at www.genesis-biopharma.com. An archived version will be available for 30 days.

Genesis Biopharma recently named Marvin S. Hausman M.D. as Chief Science Officer. Dr. Hausman has 30 years of drug development and clinical care experience at various pharmaceutical companies.

"We are very fortunate to have Marvin Hausman join the team at Genesis Biopharma," said Anthony J. Cataldo, President and Chief Executive Officer. "Dr. Hausman has an outstanding track record in identifying and developing breakthrough medical technologies, and in building companies. I believe his ability to form successful partnerships and strategic alliances will be an important asset as we grow the Company and create shareholder value."

Genesis Biopharma is a development-stage biotechnology company engaged in the development of targeted cancer therapies.

For more information about the company, visit www.genesis-biopharma.com.

Distributed by IntelBuilder Social Media Platform